Progress in neuro-psychopharmacology最新文献_第4页

An investigation of the interaction between the reinforcing properties of food and ethanol using the place preference paradigm 利用位置偏好范式研究食物和乙醇强化特性之间的相互作用

Progress in neuro-psychopharmacology Pub Date : 1981-01-01 Epub Date: 2004-05-07 DOI: 10.1016/0364-7722(81)90057-6

Robert B. Stewart, Larry A. Grupp

{"title":"An investigation of the interaction between the reinforcing properties of food and ethanol using the place preference paradigm","authors":"Robert B. Stewart, Larry A. Grupp","doi":"10.1016/0364-7722(81)90057-6","DOIUrl":"10.1016/0364-7722(81)90057-6","url":null,"abstract":"<div><ul><li>1.1. For three groups of rats, intraperitoneal injections of either 250, 500, or 1000 mg/kg ethanol were paired with a distinctive environment and later a choice was offered between that environment and one that had previously been associated with saline injections.</li><li>2.2. For a second set of three groups of animals the identical procedure was followed except that food was available in both the environment paired with ethanol and the one paired with saline.</li><li>3.3. The rats showed no preference or aversion for the environment paired with the 250 mg/kg dose either when the drug was given alone or when combined with the availability of food. No preference or aversion for the 500 mg/kg dose was indicated when the drug was given alone, but the same dose combined with food was preferred to food plus saline. The 1000 mg/kg dose was found to be aversive when given by itself, yet the same dose was neither aversive nor preferred when combined with the availability of food.</li><li>4.4. These findings suggest that ethanol can interact with food, a positive reinforcer, in ways that cannot be predicted from the effect of the drug when presented alone.</li></ul></div>","PeriodicalId":20801,"journal":{"name":"Progress in neuro-psychopharmacology","volume":"5 5","pages":"Pages 609-613"},"PeriodicalIF":0.0,"publicationDate":"1981-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0364-7722(81)90057-6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18351900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 50

Anxiety states, phobic and obsessive-compulsive disorders. Clinical picture, differential diagnostic and management 焦虑状态，恐惧症和强迫症。临床表现、鉴别诊断及处理

Progress in neuro-psychopharmacology Pub Date : 1981-01-01 Epub Date: 2004-05-07 DOI: 10.1016/0364-7722(81)90067-9

Isaac M. Marks

引用次数: 2

News and intercommunications in neuro-psychopharmacology 神经精神药理学的新闻与交流

Progress in neuro-psychopharmacology Pub Date : 1981-01-01 Epub Date: 2004-05-07 DOI: 10.1016/0364-7722(81)90095-3

引用次数: 0

A comparative study of the therapeutic effect and cardiotoxicity of dothiepin HC1 and doxepin HC1 in reactive depression 多硫平HC1与多硫平HC1治疗反应性抑郁症的疗效及心脏毒性比较研究

Progress in neuro-psychopharmacology Pub Date : 1981-01-01 Epub Date: 2004-05-07 DOI: 10.1016/0364-7722(81)90090-4

Larry Evans, John Cox

引用次数: 2

News and intercommunications in neuro-psychopharmacology 神经精神药理学的新闻与交流

Progress in neuro-psychopharmacology Pub Date : 1981-01-01 Epub Date: 2004-05-07 DOI: 10.1016/0364-7722(81)90083-7

引用次数: 0

Absence of orthostatic hypotension in depressed patients treated with bupropion 安非他酮治疗抑郁症患者无体位性低血压

Progress in neuro-psychopharmacology Pub Date : 1981-01-01 Epub Date: 2004-05-07 DOI: 10.1016/0364-7722(81)90030-8

Guy Chouinard , Lawrence Annable , Robert Langlois

{"title":"Absence of orthostatic hypotension in depressed patients treated with bupropion","authors":"Guy Chouinard , Lawrence Annable , Robert Langlois","doi":"10.1016/0364-7722(81)90030-8","DOIUrl":"10.1016/0364-7722(81)90030-8","url":null,"abstract":"<div><ul><li>1.1. Bupropion HCI (Wellbutrin®), a new antidepressant, has been reported to have low cardiovascular toxicity as a result of its specific inhibiting effect on the re-uptake of dopamine.</li><li>2.2. In order to investigate its effect on the cardiovascular system we administered bupropion for two weeks to 5 depressed patients who manifested clinically significant orthostatic hypotension while being treated with tricyclic antidepressants. Treatment with bupropion was preceded by one week of placebo washout.</li><li>3.3. Curing bupropion treatment none of the patients manifested significant orthostatic hypotension: in the 4 patients who completed the study the mean difference between supine and standing systolic blood pressure after 14 days of bupropion treatment (8.3 ± 2.5 mm Hg) was the same as after 7 days of placebo treatment (8.3 ± 3.2 mm Hg) and significantly (p < .001) lower than during treatment with tricyclics (22.3 ± 1.4 mm Hg).</li><li>4.4. Thus, buproprion appears to have the advantage that it does not induce orthostatic hypotension, which is potentially important in the treatment of the elderly and those with cardiovascular disease.</li></ul></div>","PeriodicalId":20801,"journal":{"name":"Progress in neuro-psychopharmacology","volume":"5 5","pages":"Pages 483-490"},"PeriodicalIF":0.0,"publicationDate":"1981-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0364-7722(81)90030-8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17854770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

Predicting stimulant effectiveness in hyperactive children with a repeatable neuropsychological battery: A preliminary study 用可重复的神经心理学电池预测多动症儿童的兴奋剂有效性:一项初步研究

Progress in neuro-psychopharmacology Pub Date : 1981-01-01 Epub Date: 2004-04-26 DOI: 10.1016/0364-7722(81)90006-0

Barry E. Golinko, Phillip M. Rennick, Ronald F. Lewis

引用次数: 4

The prolactin response in patients receiving neuroleptic therapy. The effect of fluphenazine decanoate 接受抗精神病药物治疗患者的催乳素反应。癸酸氟非那嗪的作用

Progress in neuro-psychopharmacology Pub Date : 1981-01-01 Epub Date: 2004-04-26 DOI: 10.1016/0364-7722(81)90007-2

Andrea Dotti , Onofrio Lostia , Ivo A. Rubino , Giuseppe Bersant , Luciana Carilli , Domenico Zorretta

{"title":"The prolactin response in patients receiving neuroleptic therapy. The effect of fluphenazine decanoate","authors":"Andrea Dotti , Onofrio Lostia , Ivo A. Rubino , Giuseppe Bersant , Luciana Carilli , Domenico Zorretta","doi":"10.1016/0364-7722(81)90007-2","DOIUrl":"10.1016/0364-7722(81)90007-2","url":null,"abstract":"<div><ul><li>1.1. Fluphenazine decanoate (FD) 50 mg was administered to 15 patients. The patient population was divided into three groups: i) Group A including 5 subjects who had never been treated before; ii) Group B including 5 subjects treated with neuroleptics for at least one year, but who had discontinued the drugs for at least three months and iii) Group C including 5 subjects who had been chronically treated with neuroleptics for at least two years.</li><li>2.2. The increase in plasma level of the hormone prolactin (PRL) after the administration of FD was different in the three groups. The patients never treated before showed the highest “PRL response”, which had a great variability among all patients.</li><li>3.3. The “PRL response” did not correlate neither with psychopathological changes nor with extrapyramidal side effects.</li><li>4.4. The “PRL response” did not seem to be a useful tool in predicting the appropriate dosage and interval of the FD administration in a given patient.</li></ul></div>","PeriodicalId":20801,"journal":{"name":"Progress in neuro-psychopharmacology","volume":"5 1","pages":"Pages 69-77"},"PeriodicalIF":0.0,"publicationDate":"1981-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0364-7722(81)90007-2","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18293370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

Effect of chronic treatment with haloperidol on serum prolactin, striatal opiate receptors and β-endorphin content in rat brain and pituitary 氟哌啶醇慢性治疗对大鼠血清催乳素、纹状体阿片受体及脑垂体β-内啡肽含量的影响

Progress in neuro-psychopharmacology Pub Date : 1981-01-01 Epub Date: 2004-05-07 DOI: 10.1016/0364-7722(81)90044-8

Nobumasa Kato, Kanhaiya R. Shah, Henry G. Friesen, Viktor Havlicek

{"title":"Effect of chronic treatment with haloperidol on serum prolactin, striatal opiate receptors and β-endorphin content in rat brain and pituitary","authors":"Nobumasa Kato, Kanhaiya R. Shah, Henry G. Friesen, Viktor Havlicek","doi":"10.1016/0364-7722(81)90044-8","DOIUrl":"https://doi.org/10.1016/0364-7722(81)90044-8","url":null,"abstract":"<div><ul><li>1.1. Rats were treated for 21 days with haloperidol (2mg/kg/day) and prolactin levels were measured serially. The increase in prolactin was obvious throughout the treatment and was even more prominent after repeated injections.</li><li>2.2. Immunoreactive β-endorphin levels were increased in the pituitary, whereas decreased in N. accumbens in rats chronically treated with haloperidol. The opiate receptor binding in the striatum showed no change in treated rats as compared with controls.</li><li>3.3. The present study suggests that 1) tolerance does not develop in prolactin-increasing action of haloperidol; 2) dopamine receptors have a role in the control of immunoreactive β-endorphin in some brain areas; 3) the various dopaminergic pathways in the brain respond differently to chronic treatment with haloperidol in terms of immunoreactive β-endorphin regulation.</li></ul></div>","PeriodicalId":20801,"journal":{"name":"Progress in neuro-psychopharmacology","volume":"5 5","pages":"Pages 549-552"},"PeriodicalIF":0.0,"publicationDate":"1981-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0364-7722(81)90044-8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91756680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 9

Clinical pharmacology of senile dementia 老年性痴呆的临床药理学

Progress in neuro-psychopharmacology Pub Date : 1981-01-01 Epub Date: 2004-05-07 DOI: 10.1016/0364-7722(81)90026-6

M. Fisman

引用次数: 7